Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Learning to distinguish progressive and non-progressive ductal carcinoma in situ.
Casasent AK, Almekinders MM, Mulder C, Bhattacharjee P, Collyar D, Thompson AM, Jonkers J, Lips EH, van Rheenen J, Hwang ES, Nik-Zainal S, Navin NE, Wesseling J; Grand Challenge PRECISION Consortium. Casasent AK, et al. Among authors: almekinders mm. Nat Rev Cancer. 2022 Dec;22(12):663-678. doi: 10.1038/s41568-022-00512-y. Epub 2022 Oct 19. Nat Rev Cancer. 2022. PMID: 36261705 Review.
Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.
Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, Bierman C, van Leeuwen FE, Rutgers EJ, Schmidt MK, Lips EH, Wesseling J. Visser LL, et al. Among authors: almekinders mm. Clin Cancer Res. 2018 Aug 1;24(15):3593-3601. doi: 10.1158/1078-0432.CCR-18-0201. Epub 2018 Apr 23. Clin Cancer Res. 2018. PMID: 29685879
Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
Visser LL, Elshof LE, Van de Vijver K, Groen EJ, Almekinders MM, Sanders J, Bierman C, Peters D, Hofland I, Broeks A, van Leeuwen FE, Rutgers EJT, Schmidt MK, Schaapveld M, Lips EH, Wesseling J. Visser LL, et al. Among authors: almekinders mm. Am J Surg Pathol. 2019 Nov;43(11):1574-1582. doi: 10.1097/PAS.0000000000001306. Am J Surg Pathol. 2019. PMID: 31206365
Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.
Groen EJ, Hudecek J, Mulder L, van Seijen M, Almekinders MM, Alexov S, Kovács A, Ryska A, Varga Z, Andreu Navarro FJ, Bianchi S, Vreuls W, Balslev E, Boot MV, Kulka J, Chmielik E, Barbé E, de Rooij MJ, Vos W, Farkas A, Leeuwis-Fedorovich NE, Regitnig P, Westenend PJ, Kooreman LFS, Quinn C, Floris G, Cserni G, van Diest PJ, Lips EH, Schaapveld M, Wesseling J; Grand Challenge PRECISION consortium. Groen EJ, et al. Among authors: almekinders mm. Breast Cancer Res Treat. 2020 Oct;183(3):759-770. doi: 10.1007/s10549-020-05816-x. Epub 2020 Jul 30. Breast Cancer Res Treat. 2020. PMID: 32734520 Free PMC article.
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.
Almekinders MM, Bismeijer T, Kumar T, Yang F, Thijssen B, van der Linden R, van Rooijen C, Vonk S, Sun B, Parra Cuentas ER, Wistuba II, Krishnamurthy S, Visser LL, Seignette IM, Hofland I, Sanders J, Broeks A, Love JK, Menegaz B, Wessels L, Thompson AM, de Visser KE, Hooijberg E, Lips E, Futreal A, Wesseling J; Grand Challenge PRECISION Consortium. Almekinders MM, et al. Br J Cancer. 2022 Oct;127(7):1201-1213. doi: 10.1038/s41416-022-01888-2. Epub 2022 Jun 29. Br J Cancer. 2022. PMID: 35768550 Free PMC article.
Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ.
Casasent AK, Almekinders MM, Mulder C, Bhattacharjee P, Collyar D, Thompson AM, Jonkers J, Lips EH, van Rheenen J, Hwang ES, Nik-Zainal S, Navin NE, Wesseling J; Grand Challenge PRECISION Consortium. Casasent AK, et al. Among authors: almekinders mm. Nat Rev Cancer. 2023 Feb;23(2):112. doi: 10.1038/s41568-022-00542-6. Nat Rev Cancer. 2023. PMID: 36522469 No abstract available.
A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.
Hutten SJ, de Bruijn R, Lutz C, Badoux M, Eijkman T, Chao X, Ciwinska M, Sheinman M, Messal H, Herencia-Ropero A, Kristel P, Mulder L, van der Waal R, Sanders J, Almekinders MM, Llop-Guevara A, Davies HR, van Haren MJ, Martin NI, Behbod F, Nik-Zainal S, Serra V, van Rheenen J, Lips EH, Wessels LFA; Grand Challenge PRECISION Consortium; Wesseling J, Scheele CLGJ, Jonkers J. Hutten SJ, et al. Among authors: almekinders mm. Cancer Cell. 2023 May 8;41(5):986-1002.e9. doi: 10.1016/j.ccell.2023.04.002. Epub 2023 Apr 27. Cancer Cell. 2023. PMID: 37116492 Free PMC article.
Artificial intelligence-based morphometric signature to identify ductal carcinoma in situ with low risk of progression to invasive breast cancer.
Sobral-Leite M, Castillo S, Vonk S, Melillo X, Lam N, de Bruijn B, Hagos Y, Sanders J, Almekinders M, Visser L, Groen E, Kristel P, Ercan C, Azarang L, Yuan Y; Grand Challenge PRECISION Consortium; Menezes R, Lips E, Wesseling J. Sobral-Leite M, et al. Res Sq [Preprint]. 2023 Dec 13:rs.3.rs-3639521. doi: 10.21203/rs.3.rs-3639521/v1. Res Sq. 2023. PMID: 38168198 Free PMC article. Preprint.
Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1-NDRG1 deregulation.
Mayayo-Peralta I, Debets DO, Prekovic S, Schuurman K, Beerthuijzen S, Almekinders M, Sanders J, Moelans CB, Saleiro S, Wesseling J, van Diest PJ, Henrique R, Jerónimo C, Altelaar M, Zwart W. Mayayo-Peralta I, et al. Mol Oncol. 2024 Jan;18(1):156-169. doi: 10.1002/1878-0261.13540. Epub 2023 Nov 2. Mol Oncol. 2024. PMID: 37854018 Free PMC article.
13 results